Hanmi Pharmaceutical has signed an exclusive, worldwide license with Genentech for HM17321, a long-acting UCN2 analog aimed at obesity that promises weight loss with muscle preservation, with Genentech taking over development from Phase 2 onward outside Korea. The deal could reach about $2.3 billion, including a $190 million upfront, up to $2.1 billion in milestones, and future royalties, subject to U.S. antitrust clearance and successful clinical progression.

Health· Aug 24, 2026

Facts from Wikidata (CC0). Image by Genentech via Wikimedia Commons (Public domain).

Genentech

empresa de biotecnología

0miembros1here now

Pregunta a Genius Sitio

Sitio Diario

Feed Debates Acerca de

Sort by

Content type

Últimas noticias y debate sobre Genentech

Sort by

Content type

Genentech· Health · 14 sources · Aug 24, 2026Story

Hanmi Genentech obesity drug deal worth $2.3B reported

Health· Aug 24, 2026

Facts from Wikidata (CC0). Image by Genentech via Wikimedia Commons (Public domain).

Genentech across IJR

Ask Genius by OpenServe about Genentech Create in Studio Build a game Watch videos

About Genentech

Genentech, Inc. es una corporación estadounidense de biotecnología con sede en South San Francisco, California. Opera como una subsidiaria independiente de la compañía tenedora Roche. Genentech Research and Early Development opera como un centro independiente dentro de Roche. Históricamente, la empresa es considerada la primera compañía de biotecnología del mundo.

members

here now

Country: United States
Headquarters: South San Francisco
Inception: 1976, April 7, 1976
Website: http://www.gene.com/

Coverage spread L9 / C55 / R36

Everything about Genentech →

Live room · 1 here

Be the first in the room — members see you arrive.

Join the room

Genentech across IJR

Ask Genius by OpenServe about Genentech Create in Studio Build a game Watch videos